Neurocrine Biosciences Inc. (NBIX)
Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago.
Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Neurocrine (NBIX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Reasons Why Investors Should Consider Betting on Neurocrine Stock
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno
Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts.
